Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 -1.28%75 Altman Z-Score is 37.18 as of Jul. 21, 2026, which is 14% below its 10-year median of 42.99. GuruFocus rates ROCO:6620 with a GF Score™ of 75/100 and a GF Value™ of NT$183.95 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 952 Drug Manufacturers companies, Handa Pharmaceuticals ranks better than 98.42% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 37.93 is strong.
Handa Pharmaceuticals has a Altman Z-Score of 37.18, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Handa Pharmaceuticals's Altman Z-Score or its related term are showing as below:
ROCO:6620'
s Altman Z-Score Range Over the Past 10 Years
Min: 21.01 Med: 42.99 Max: 166.99
Current: 37.93
During the past 12 years, Handa Pharmaceuticals's highest Altman Z-Score was 166.99. The lowest was 21.01. And the median was 42.99.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Handa Pharmaceuticals Altman Z-Score Related Terms
Handa Pharmaceuticals Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Handa Pharmaceuticals (ROCO:6620) has a Altman Z-Score of 37.18 as of Jul. 21, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Handa Pharmaceuticals and its competitors. This is 14% below median its historical median of 42.99. Over the past decade, Handa Pharmaceuticals' Altman Z-Score has ranged from 21.01 to 166.99. According to the industry distribution chart, Handa Pharmaceuticals ranks #15 out of 952 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Handa Pharmaceuticals' Altman Z-Score too high?
Handa Pharmaceuticals' current Altman Z-Score of 37.18 is 14% below median its 10-year median of 42.99. Over the past 10 years, this metric has ranged from a low of 21.01 to a high of 166.99. The Drug Manufacturers industry median Altman Z-Score is 3.22. Handa Pharmaceuticals' value of 37.18 is 1054.7% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #15 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #15 out of 952 companies for Altman Z-Score. This places Handa Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.22. Handa Pharmaceuticals' value of 37.18 is 1054.7% above this benchmark. Historically, Handa Pharmaceuticals' own Altman Z-Score has ranged from 21.01 to 166.99 over the past decade. While the company's 10-year median is 42.99 vs. the industry median of 3.22, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.22, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current Altman Z-Score of 37.18 is 1054.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current Altman Z-Score is 37.18, which is 14% below median its own 10-year median of 42.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$183.95, compared to a current price of NT$84.70 — trading 54% below its estimated fair value. The current Altman Z-Score is 37.18, which is 14% below median its 10-year median of 42.99 and 1054.7% above the Drug Manufacturers industry median of 3.22. Handa Pharmaceuticals' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Altman Z-Score is 37.18 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95.
GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ROCO:6620:
Altman Z-Score: 37.18 (14% below median its 10-year median of 42.99)
GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
Industry Position: 1054.7% above the Drug Manufacturers median (#15 of 952)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score
Get the complete analysis for ROCO:6620
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
